ID: ALA3326671

Max Phase: Preclinical

Molecular Formula: C21H22F4N4O7S

Molecular Weight: 550.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1nc(S(C)(=O)=O)ccc1Oc1ncnc(OC2CCN(C(=O)OC3(C(F)(F)F)COC3)CC2)c1F

Standard InChI:  InChI=1S/C21H22F4N4O7S/c1-12-14(3-4-15(28-12)37(2,31)32)35-18-16(22)17(26-11-27-18)34-13-5-7-29(8-6-13)19(30)36-20(9-33-10-20)21(23,24)25/h3-4,11,13H,5-10H2,1-2H3

Standard InChI Key:  PMXJGYIIFVVUMX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 550.49

Molecular Weight (Monoisotopic): 550.1145

AlogP: 2.83

#Rotatable Bonds: 6

Polar Surface Area: 130.04

Molecular Species: NEUTRAL

HBA: 10

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 0.67

CX LogP: 1.67

CX LogD: 1.67

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.50

Np Likeness Score: -0.88

References

1. Buzard DJ, Kim SH, Lehmann J, Han S, Calderon I, Wong A, Kawasaki A, Narayanan S, Bhat R, Gharbaoui T, Lopez L, Yue D, Whelan K, Al-Shamma H, Unett DJ, Shu HH, Tung SF, Chang S, Chuang CF, Morgan M, Sadeque A, Chu ZL, Leonard JN, Jones RM..  (2014)  Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.,  24  (17): [PMID:25088191] [10.1016/j.bmcl.2014.06.071]

Source

Source(1):

• Scientific Literature